Novo Nordisk A/S (NYSE:NVO) Shares Sold by Pinpoint Asset Management Ltd

Pinpoint Asset Management Ltd lessened its holdings in Novo Nordisk A/S (NYSE:NVO - Free Report) by 70.9% during the 1st quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 2,692 shares of the company's stock after selling 6,546 shares during the period. Pinpoint Asset Management Ltd's holdings in Novo Nordisk A/S were worth $187,000 as of its most recent filing with the Securities & Exchange Commission.

Several other large investors have also modified their holdings of NVO. Revolve Wealth Partners LLC lifted its stake in shares of Novo Nordisk A/S by 8.7% in the 4th quarter. Revolve Wealth Partners LLC now owns 2,490 shares of the company's stock valued at $214,000 after purchasing an additional 200 shares during the last quarter. Trek Financial LLC acquired a new position in shares of Novo Nordisk A/S in the 4th quarter valued at $212,000. Bank of Nova Scotia lifted its stake in shares of Novo Nordisk A/S by 62.5% in the 4th quarter. Bank of Nova Scotia now owns 12,650 shares of the company's stock valued at $1,092,000 after purchasing an additional 4,866 shares during the last quarter. CenterBook Partners LP lifted its stake in shares of Novo Nordisk A/S by 45.9% in the 4th quarter. CenterBook Partners LP now owns 5,557 shares of the company's stock valued at $478,000 after purchasing an additional 1,749 shares during the last quarter. Finally, Phoenix Financial Ltd. lifted its stake in shares of Novo Nordisk A/S by 37.5% in the 4th quarter. Phoenix Financial Ltd. now owns 19,140 shares of the company's stock valued at $1,647,000 after purchasing an additional 5,220 shares during the last quarter. Institutional investors and hedge funds own 11.54% of the company's stock.

Novo Nordisk A/S Price Performance

Shares of NYSE NVO opened at $45.31 on Thursday. The stock's 50-day moving average is $67.96 and its two-hundred day moving average is $72.01. The company has a debt-to-equity ratio of 0.70, a current ratio of 0.74 and a quick ratio of 0.56. Novo Nordisk A/S has a 1-year low of $45.05 and a 1-year high of $139.74. The company has a market cap of $202.31 billion, a price-to-earnings ratio of 13.41, a price-to-earnings-growth ratio of 1.43 and a beta of 0.63.

Novo Nordisk A/S (NYSE:NVO - Get Free Report) last issued its quarterly earnings results on Wednesday, August 6th. The company reported $0.97 earnings per share for the quarter, topping the consensus estimate of $0.89 by $0.08. Novo Nordisk A/S had a return on equity of 80.94% and a net margin of 34.52%. Analysts forecast that Novo Nordisk A/S will post 3.84 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

Several equities analysts have recently commented on the company. Barclays reaffirmed an "equal weight" rating on shares of Novo Nordisk A/S in a research note on Wednesday, July 30th. UBS Group downgraded Novo Nordisk A/S from a "buy" rating to a "neutral" rating in a report on Tuesday. Dbs Bank downgraded Novo Nordisk A/S to a "sell" rating in a report on Friday, April 25th. Wall Street Zen downgraded Novo Nordisk A/S from a "buy" rating to a "hold" rating in a report on Saturday, August 2nd. Finally, HSBC downgraded Novo Nordisk A/S from a "buy" rating to a "hold" rating and set a $57.00 price objective on the stock. in a report on Thursday, July 31st. Two analysts have rated the stock with a sell rating, ten have given a hold rating and two have issued a buy rating to the stock. According to MarketBeat.com, the company has a consensus rating of "Hold" and an average price target of $93.67.

Novo Nordisk A/S Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.